Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [bbd529ae-065a-4214-b09d-1d9020fd932d] => Array ( [runtime-id] => bbd529ae-065a-4214-b09d-1d9020fd932d [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [9e22db07-4f94-4334-a453-adfb4c3a099c] => Array ( [runtime-id] => 9e22db07-4f94-4334-a453-adfb4c3a099c [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;604fac0265f7344bf33eb35dca1b451d76bcc2a0 ) ) ) 1naresh2naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [bbd529ae-065a-4214-b09d-1d9020fd932d] => Array
        (
            [runtime-id] => bbd529ae-065a-4214-b09d-1d9020fd932d
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [9e22db07-4f94-4334-a453-adfb4c3a099c] => Array
                        (
                            [runtime-id] => 9e22db07-4f94-4334-a453-adfb4c3a099c
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;604fac0265f7344bf33eb35dca1b451d76bcc2a0
                )

        )

)

Table 1: Cohort details
Patient No./Age (y)/Sex EDSS ΔY₁ ΔY₂ WBNAA Concentration (mM) Group^* Medications
1/27.6/F 2.5 0.53 2.78 7.14 R Avonex
2/28.1/F 1 0.26 1.68 14.52 S Copaxone
3/29.8/F 0 3.32 3.83 12.87 M Avonex
4/31.3/F 1.5 8.19 8.94 9.96 M Avonex
5/33.1/M 1 2.7 3.2 12.69 M Avonex
6/34.5/F 1.5 6.47 6.47 13.87 S Avonex
7/34.7/F 2 0.15 3.62 9.65 R/M^† Copaxone
8/37.2/F 3 2.55 2.72 7.85 R Avonex
9/37.9/F 3 0.32 0.32 9.37 R N/A
10/38.4/M 1.5 0.95 18.29 13.55 S Avonex
11/41.5/F 2 0.65 1.07 10.91 R Avonex
12/42.8/F 1 1.16 1.24 13.9 S Avonex
13/44.3/F 2 7.37 7.53 10.28 M N/A
14/45.1/M 0 3.05 11.06 10.98 M N/A
15/45.7/M 2.5 2.24 2.24 10.82 M Avonex
16/54.9/F 6 2.3 4.55 16.01 S Bestaseron
Average 2.1 2.64 4.97 11.39 ± 2.5 
Note:—EDSS indicates Expanded Disability Status Scale; Δ Y₁, disease duration since clinically definite diagnosis (years); Δ Y₂, disease duration from first clinical event (years); WBNAA, whole-brain N-acetylaspartate. The average age of patients studied was 37.9 ± 7.7.
* Subgroup notations are S, stable; M, moderate; R, rapid.
† Assignment changed from rapid (based on Δ Y₁₎ to moderate when estimated from Δ Y₂ disease duration.

Patient No./Age (y)/Sex	EDSS	ΔY₁	ΔY₂	WBNAA Concentration (mM)	Group^*	Medications
1/27.6/F	2.5	0.53	2.78	7.14	R	Avonex
2/28.1/F	1	0.26	1.68	14.52	S	Copaxone
3/29.8/F	0	3.32	3.83	12.87	M	Avonex
4/31.3/F	1.5	8.19	8.94	9.96	M	Avonex
5/33.1/M	1	2.7	3.2	12.69	M	Avonex
6/34.5/F	1.5	6.47	6.47	13.87	S	Avonex
7/34.7/F	2	0.15	3.62	9.65	R/M^†	Copaxone
8/37.2/F	3	2.55	2.72	7.85	R	Avonex
9/37.9/F	3	0.32	0.32	9.37	R	N/A
10/38.4/M	1.5	0.95	18.29	13.55	S	Avonex
11/41.5/F	2	0.65	1.07	10.91	R	Avonex
12/42.8/F	1	1.16	1.24	13.9	S	Avonex
13/44.3/F	2	7.37	7.53	10.28	M	N/A
14/45.1/M	0	3.05	11.06	10.98	M	N/A
15/45.7/M	2.5	2.24	2.24	10.82	M	Avonex
16/54.9/F	6	2.3	4.55	16.01	S	Bestaseron
Average	2.1	2.64	4.97	11.39 ± 2.5